Clinical Trial Update: A Safety and Effectiveness Study of JNJ-18038683 in Patients With Moderate to Severe Depression [Phase 2]

View source ↗

Summary

Phase 2 safety and effectiveness study of JNJ-18038683 in adults with Major Depressive Disorder has been completed. The results assess safety and preliminary ef…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• JNJ-18038683

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Major Depressive Disorder | Phase 2 | Status: COMPLETED